NCT03749083View on ClinicalTrials.gov

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

December 31, 2019

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2024

Conditions
Gastrointestinal Malignancies
Interventions
OTHER

The Functional Assessment of Cancer Therapy- Colorectal

The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.

Trial Locations (4)

02214

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women Hospital, Boston

02459

Newton-Wellesley Hospital, Newton

Sponsors

Collaborators (1)

Clinical Genomics
All Listed Sponsors
collaborator

Clinical Genomics

UNKNOWN

lead

Massachusetts General Hospital

OTHER

NCT03749083 - A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer | Biotech Hunter | Biotech Hunter